# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for c...
Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy and lowers the price target fro...
Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate o...
– SEC Filing